HSDT trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HSDT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Solana Company (HSDT) has a Wall Street consensus price target of N/A, based on estimates from 4 covering analysts. The company has a market capitalization of $95M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HSDT trades at a trailing P/E of -0.9x. Analysts expect EPS to grow +63.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
STIMNeuronetics, Inc. | $84M | $1.20 | $8.00 | +550.4% | Buy | — | 7 |
LFSTLifeStance Health Group, Inc. | $3.6B | $9.21 | $9.90 | +10.2% | Buy | 66.0x | 11 |
MBOTMicrobot Medical Inc. | $84M | $1.85 | $5.50 | +195.7% | Buy | — | 3 |
GKOSGlaukos Corporation | $7.7B | $131.19 | $151.25 | +15.7% | Buy | — | 24 |
NVCRNovoCure Limited | $1.5B | $13.61 | $33.00 | +131.1% | Buy | — | 15 |
LIVNLivaNova PLC | $4.3B | $78.71 | $79.86 | +1.7% | Buy | 18.5x | 14 |
MDTMedtronic plc | $101.8B | $79.27 | $95.80 | +20.7% | Buy | 13.3x | 51 |
BSXBoston Scientific Corporation | $65.9B | $44.33 | $82.90 | +83.0% | Buy | 13.5x | 44 |
ABTAbbott Laboratories | $152.6B | $87.78 | $127.46 | +44.2% | Buy | 16.1x | 41 |
SYKStryker Corporation | $116.7B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
Quick answers to the most common questions about buying HSDT stock.
The consensus price target for HSDT is $N/A, close to the current price of $1.63 (N/A% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
HSDT has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
HSDT's current price is $1.63 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for HSDT, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
HSDT is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HSDT stock forecast based on 4 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
HSDT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HSDT analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.